
The rival treatment to Novartis’ Lucentis has posted encouraging new study results in patients with diabetic macular oedema (DME). In …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

